Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcoma

This phase I/II trial studies the side effects and best dose of proton-spatially fractionated radiotherapy (P-SFRT) and to see how well it works with standard radiation therapy in treating patients with newly diagnosed retroperitoneal soft tissue sarcoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard spatially fractionated radiotherapy (SFRT) refers to how the radiation is delivered to the tumor. SFRT means that different parts of the tumor are receiving different doses of radiation (fractionation) through beams that

Trial Details

NCT ID
NCT06327477
Phase
PHASE1 / PHASE2
Sponsor
Northwestern University
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Biopsy
  • Biospecimen Collection
  • Computed Tomography
  • Intensity-Modulated Radiation Therapy
  • Resection
  • Spatially-fractionated Radiation Therapy
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

  • Patients must have newly diagnosed, histologically or cytologically confirmed, untreated retroperitoneal soft tissue sarcoma Note: The soft-tissue …
  • Patients must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1.
  • Patients must be age ≥ 18 years on day of signing any informed consent documents
  • Patients must exhibit a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) performance scale or \>70% on the Karnofsky S…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →